Helix BioMedix IncOTC Pink - Limited Information:HXBM
- LAST PRICE23.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 23.2700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Helix BioMedix Inc | 5.2M | -1.5x | --- |
Seelos Therapeutics Inc | 4.1M | 0.0x | --- |
Gamida Cell Ltd | 2.4M | 0.0x | --- |
Xenetic Biosciences Inc | 5.9M | -1.4x | --- |
OpGen Inc | 5.6M | -0.1x | --- |
Senestech Inc | 3.9M | 0.0x | --- |
Company Information
Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Company’s lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the body’s innate immunity.
Contact Information
- Headquarters
- SUITE 112, 22121 17TH AVE SEBOTHELL, WA, United States 98021
- Phone
- 425-402-8400
- Fax
- 425-806-2999
Executives
- Chairman of the Board
- R. Stephen Beatty
- President, Chief Executive Officer, Director
- Robin Carmichael
- Independent Director
- John Clifford
- Independent Director
- Richard Cohen
- Independent Director
- William Goolsbee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.2M |
|---|---|
Revenue (TTM) | $2.1M |
Shares Outstanding | 224.7K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-15.60 |
Book Value | $15.31 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -117.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
